Pulmonx to Present at the Bank of America Securities 2026 Health Care Conference
Pulmonx (Nasdaq: LUNG) will present at the Bank of America Securities 2026 Health Care Conference in Las Vegas on Tuesday, May 12, 2026 at 8:15 AM PT / 11:15 AM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Pulmonx (Nasdaq: LUNG) will present at the Bank of America Securities 2026 Health Care Conference in Las Vegas on Tuesday, May 12, 2026 at 8:15 AM PT / 11:15 AM ET. A live and archived webcast will be available in the Investors section of the company website.
Details
News Market Reaction – LUNG
On Apr 29, the first trading day after this news, LUNG closed 2.44% below the previous close.
Data tracked by StockTitan Argus for the Apr 29 session.
Key Figures
- Conference date
- May 12, 2026
- Bank of America Securities 2026 Health Care Conference presentation date
- Presentation time PT
- 8:15 AM PT
- Scheduled start of Pulmonx conference presentation
- Presentation time ET
- 11:15 AM ET
- Eastern time for Pulmonx conference presentation
Historical Context
-
Scheduled Q1 2026 results release and earnings call details.
-
Reported 2025 results and 2026 guidance with revenue growth and margin detail.
-
Closed new five-year credit facility up to $60M to refinance debt.
-
Announced timing and webcast details for Q4 and 2025 results.
-
Granted 1,625,000 inducement equity awards to new executives under plan.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be presenting at the Bank of America Securities 2026 Health Care Conference in Las Vegas on Tuesday, May 12, 2026, at 8:15 AM PT / 11:15 AM ET.
A live and archived webcast of the presentation will be available on “Investors” section of the Pulmonx website at https://investors.pulmonx.com/.
About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System, LungTraXTM Platform, and StratX® Lung Analysis Reports are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit www.Pulmonx.com.
Pulmonx®, AeriSeal®, Chartis®, StratX®, and Zephyr® are registered trademarks and LungTraXTM is a trademark of Pulmonx Corporation.
Contact
Brian Johnston
Gilmartin Group
investors@pulmonx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.